 This is analogous to what occurs in women with a defective due to complete androgen insensitivity syndrome.Demasculinizing and feminizing effects of bicalutamide in those assigned male at birth include breast development, reduced male-pattern hair, decreased muscle mass, feminine changes in fat distribution, decreased sex drive, and reduced spontaneous erections.Dosages of bicalutamide of 25 to 50 mg/day have been employed and recommended for use in transgender females.